Abstract: The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinol preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis sativa and/or Cannabis indica and/or Cannabis ruderalis and/or citrus fruits, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against sleeping disorders, in particular insomnia, and anxiety disorders including ADHD.
Type:
Application
Filed:
June 13, 2014
Publication date:
May 12, 2016
Inventors:
Dorothy Helen BRAY, Mario LAP, Alfredo Carlos DUPETIT
Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing and treating non-alcoholic fatty liver disease, which comprises red ginseng concentrate having enhanced Compound K as an effective ingredient by using an enzyme conversion technique.
Type:
Application
Filed:
November 9, 2015
Publication date:
May 12, 2016
Inventors:
Se Hee Paek, Yong Ki Seo, Ji Hye Song, Byoung Seok Moon, Heung Sop Shin, Hwa Soo Shin
Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
Abstract: The invention relates to a composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa comprising cranberry concentrate, urea, L-arginine, a buffer ensuring a pH value of the composition of 3.0 to 4.0, water and, optionally, additional active and/or auxiliary substances. The present invention also relates to a two-compartment blister pack containing the composition and to a kit comprising the two-compartment blister pack and an applicator fitting to the outlet channel of the blister pack easy to apply the composition to the desired areas.
Abstract: This invention relates to a method of treating metabolic syndrome and diabetes using a composition containing quercetin, vitamin B3, vitamin C, and a Bauhinia forficata extract.
Abstract: The present invention relates to a composition for preventing and treating gastrointestinal diseases by using Litsea japonica, and specifically, to a composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from Litsea japonica fruit as an active ingredient. According to the present invention, the essential oils extracted from Litsea japonica fruits (pure fruit, seed fruit, and seeds) and used as the active ingredient of the composition for preventing and treating gastrointestinal diseases have been confirmed to have excellent effects in an efficacy evaluation for relieving gastrointestinal diseases caused by Helicobacter pylori, which is a gastrointestinal disease factor, physical factors induced by stress, and chemical factors induced by indomethacin. Therefore, the essential oils extracted from Litsea japonica fruit (pure fruit, seed fruit, and seeds) are useful for preventing and treating gastrointestinal diseases caused by various factors.
Type:
Application
Filed:
April 30, 2014
Publication date:
May 12, 2016
Inventors:
Ju-Hyun CHO, In-Jae PARK, Yong-Hwan JUNG, Goo-Hee CHOI, Weon-Jong YOON, Sung-Hwan PARK, Ji-Hyun YUN, Soon-Ok BAIK
Abstract: The present invention provides an all-natural, topical pain relief cream, with no artificial ingredients using Bentonite U.S.P. and sterile water U.S.P. as the foundation. The cream contains as active ingredients, one or more of menthol (regular or maximum strength), and salicin (methyl salicylate), with camphor and capsaicin as optional active ingredients. The vehicle includes coconut oil and lecithin to help retain the more volatile ingredients in with cream.
Abstract: Disclosed is use of an asparagus powder in medicines, food, and health foods for treatment of anxiety and depressive mental disorders, with active ingredients in the asparagus powder including: 15.0% or more of an asparagus saponin, 8% or more of a polysaccharide, 3.0% or more of a polyphenol, and 2.0% or more of a flavone.
Type:
Application
Filed:
January 22, 2014
Publication date:
May 12, 2016
Inventors:
YUNXIANG HUANG, LONG CHENG, QIPENG YUAN
Abstract: The present invention is related to a composition for relieving joint inflammation. The present invention is also related to a method for treatment of joint inflammation, comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition. By means of inhibiting the COX-2 and NF-?B expression through the composition or the pharmaceutical composition with specific ratio, the joint inflammation and swelling could be reduced and the osteoclasts proliferation could be decreased to mitigate bone erosion, osteoporosis and degenerative arthritis.
Abstract: A method for inducing a proliferation of dopaminergic cells in a subject in need, comprising: administering a herbal medicinal composition to a subject in need, wherein the herbal medicinal composition comprises: Ginseng Radix, Glycyrrhiza uralensis, Zingiber officinale Roscoe, Cinnamomum cassia Presl., and Scutellariae Radix.
Abstract: Compositions and methods for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a GSSG and a carrier thereof. In an aspect, the carrier is a liposome. In a further aspect, the liposome is a positively charged liposome.
Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
Type:
Application
Filed:
November 6, 2014
Publication date:
May 12, 2016
Inventors:
Eric A.F. van Tol, Marieke H. Schoemaker, Gabriele Gross
Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.
Type:
Application
Filed:
November 17, 2015
Publication date:
May 12, 2016
Inventors:
Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.
Abstract: This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use.
Type:
Application
Filed:
November 13, 2015
Publication date:
May 12, 2016
Inventors:
Alyssa Panitch, John Eric Paderi, Shaili Sharma, Katherine Allison Stuart, Nelda Marie Vazquez-Portalatin
Abstract: A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.
Abstract: Compositions and methods for managing the growth, life cycle, functionality, or biological progression of cells, tissues, and organisms by introducing rhomboid proteins or peptides into the internal and external environment of the cells, tissues, and organisms. In particular, embodiments comprise compositions and methods for overcoming drug resistance in disease, and for sensitizing cells, tissues, and organisms to agents to treat disease, and methods for producing such compositions. The compositions and methods include rhomboid proteins, polypeptides, and/or peptides, and nucleic acids encoding such proteins, polypeptides, and/or and peptides, corresponding to the Arabidopsis At1g74130 or At1g25290 gene or human UBAC2 gene.
Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
Type:
Application
Filed:
June 13, 2013
Publication date:
May 12, 2016
Applicant:
Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center
Abstract: Patients with polypoidal choroidal vasculopathy receive a combination of both (i) a photodynamic therapy, such as verteporfin and (ii) a non-antibody VEGF antagonist.
Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
Type:
Application
Filed:
November 16, 2015
Publication date:
May 12, 2016
Inventors:
Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Application
Filed:
September 4, 2015
Publication date:
May 12, 2016
Inventors:
Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
Type:
Application
Filed:
January 19, 2016
Publication date:
May 12, 2016
Inventors:
Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
Abstract: The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Type:
Application
Filed:
March 6, 2014
Publication date:
May 12, 2016
Inventors:
Anthony O. CAGGIANO, Anindita GANGULY, Jennifer IACI, Tom PARRY
Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
Abstract: The present invention concerns methods and compositions for forming complexes of interferon-? with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-? and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-? alone, antibody alone, or the combination of unconjugated interferon-? and antibody.
Type:
Application
Filed:
January 18, 2016
Publication date:
May 12, 2016
Inventors:
Chien-Hsing Chang, David M. Goldenberg, Donglin Liu
Abstract: The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.
Type:
Application
Filed:
May 4, 2015
Publication date:
May 12, 2016
Inventors:
Michael Edward Christe, Thomas Andrew Hardy
Abstract: One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.
Type:
Application
Filed:
October 8, 2015
Publication date:
May 12, 2016
Applicant:
Dance Biopharm Inc.
Inventors:
John S. Patton, Ryan S. Patton, Mei-chang Kuo, Yehuda Ivri
Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a Somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
Abstract: The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
Type:
Application
Filed:
November 12, 2015
Publication date:
May 12, 2016
Inventors:
Kurt Schnecker, Eva Haidweger, Peter Turecek
Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.
Type:
Application
Filed:
December 28, 2015
Publication date:
May 12, 2016
Inventors:
Jeff Twidwell, Joel Buckley, Harold Hoium
Abstract: A method for the augmentation of immune function is described. The invention comprises a combination of ?-1,3 (4)-endoglucanohydrolase, ?-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species.
Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.
Type:
Application
Filed:
January 13, 2016
Publication date:
May 12, 2016
Inventors:
James D. Crapo, A. Mario Q Marcondes, H. Joachim Deeg
Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
Type:
Application
Filed:
November 2, 2015
Publication date:
May 12, 2016
Inventors:
Mirjam H.M. HEEMSKERK, J.H. Frederik Falkenburg
Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
Type:
Application
Filed:
September 10, 2015
Publication date:
May 12, 2016
Inventors:
Randolph J. NOELLE, Cory L. Ahonen, Ross M. Kedl
Abstract: The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.
Abstract: The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells. Cells can then be mixed with an unmethylated single stranded oligodeoxynucleotide chain adjuvant to formulate a vaccine and then administered to a subject. The vaccines can be autologous, allogeneic or hybrids thereof to the subject.
Type:
Application
Filed:
November 6, 2015
Publication date:
May 12, 2016
Inventors:
JEREMY DELK, DONALD COHEN, JOHN YANNELLI
Abstract: It is disclosed herein that B cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid DNA. Based on this finding, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines are co-administered with a B cell targeting agent, B-cell recruiting agent, or a monocyte or dendritic cell recruiting agent. To increase the immunogenicity of the DNA vaccines, the B cell targeting agent or B cell recruiting agent is administered at the same location where the DNA vaccine is administered. In contrast, the monocyte or dendritic cell recruiting agent can be administered in a different location, in order to recruit cells competing with the B cells for DNA uptake away from the location where the DNA vaccine is administered.
Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.
Type:
Application
Filed:
November 9, 2015
Publication date:
May 12, 2016
Inventors:
Alexander Douglas, Simon Draper, Adrian Hill, Andrew Williams, Joseph Illingworth
Abstract: The present application provides methods of stimulating an immune response, such as a protective immune response against Treponema pallidum infection. Such methods utilize fragments of the Tp0751 protein (such as any of SEQ ID NOs: 3-10, those N-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115). In some examples, a Tp0751 protein fragment has a mutated HEXXH site (HEXXH is the wild-type sequence). Also provided are the isolated soluble Tp0751 protein fragments that include a wild-type or mutated HEXXH site, as well as nucleic acids encoding such proteins and kits that include such proteins.
Type:
Application
Filed:
January 12, 2016
Publication date:
May 12, 2016
Applicant:
UVic Industry Partnerships Inc.
Inventors:
Caroline E. Cameron, Rebecca M. Hof, Simon A. Houston, Martin John Boulanger
Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.
Type:
Application
Filed:
June 3, 2014
Publication date:
May 12, 2016
Inventors:
Ralph Leon BIEMANS, Dominique BOUTRIAU, Philippe DENOEL, Pierre DUVIVIER, Carine GORAJ
Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
Type:
Application
Filed:
November 6, 2015
Publication date:
May 12, 2016
Inventors:
Dan T. STINCHCOMB, Jorge E. OSORIO, Charalambos D. PARTIDOS, Joseph N. BREWOO
Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
Type:
Application
Filed:
November 13, 2015
Publication date:
May 12, 2016
Applicants:
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC., VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
Inventors:
Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
Type:
Application
Filed:
November 6, 2015
Publication date:
May 12, 2016
Inventors:
Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
Type:
Application
Filed:
January 13, 2016
Publication date:
May 12, 2016
Applicant:
CureVac AG
Inventors:
Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
Abstract: This disclosure relates to methods for preparing a virosome preparation comprising viral envelope protein of at least two, preferably at least three, more preferably at least four, different enveloped viruses, as well as to virosomal preparations obtained thereby. The disclosure also relates to the use of the virosomal preparations, e.g., as a vaccine.
Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
Type:
Application
Filed:
November 10, 2015
Publication date:
May 12, 2016
Applicant:
MedImmune Limited
Inventors:
Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon
Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.